TSVT

Investor Moves

Investor	Portfolio Value	Portfolio Change	Position Change	Avg Buy Price	Current Price
Ken GriffinCitadel Advisors $-154.6K ExitQ2 2025 $155k -- --
Ken GriffinCitadel Advisors $-154.6K ExitQ2 2025 $155k -- --
Steven CohenPoint72 $-913.3K ExitQ1 2025 $913k -- --
Steven CohenPoint72 $-913.3K ExitQ1 2025 $913k -- --
Ken GriffinCitadel Advisors $59.0K AddQ1 2025 $59k -- --
Ken GriffinCitadel Advisors $59.0K AddQ1 2025 $59k -- --

Trade TSVT

About 2seventy bio, Inc.

2seventy bio, Inc. operates as a biotechnology firm specializing in cell and gene therapies, with a primary mission to discover, develop, and commercialize advanced cancer treatments within the U.S. Its pipeline notably includes idecabtagene vicleucel, marketed as ide-cel or Abecma, and bb21217, both of which are CAR-T cell therapeutic candidates specifically designed to address multiple myeloma. The company also maintains a strategic partnership with Bristol-Myers Squibb Company. Founded in 2021, its corporate headquarters are situated in Cambridge, Massachusetts.

CEO: William D. Baird III,
IPO Date: Nov 3, 2021

Market Data

Market data refresh is queued when this stock page is viewed.

Valuation

Valuation snapshot is not available yet.

Financials

Financial statement snapshot is not available yet.

Events

EarningsNov 10